摘要:
目的 探讨吸入噻托溴铵治疗中重度慢性阻塞性肺病的疗效和安全性。 方法 观察2010年6月~2011年11月门诊或住院使用噻托溴铵干粉剂(思力华,18 μg,1次/d)的慢性阻塞性肺病患者35例。比较患者治疗前及治疗3个月后肺功能、平均每日使用β受体激动剂次数及心肺功能不全患者外周血浆脑纳肽水平(BNP),记录患者治疗前3个月及治疗后3个月因病情加重入院治疗的次数,同时观察不良反应。 结果 吸入噻托溴铵后肺功能明显好转,每日使用β受体激动剂次数减少,BNP水平有明显下降,急性加重发作的次数减少,无严重不良反
Abstract:
Objective To investigate the effectiveness and safety of the inhalation of tiotropium bromide in the treatment of moderate to severe chronic obstructive pulmonary disease. Methods 35 cases with chronic obstructive pulmonary disease during 2010 June to 2011 November in our department were observed which was used by tiotropium bromide dry powder (Spirva, 18 μg, once daily) . The pulmonary function, average daily use of beta agonists times and cardiopulmonary insufficiency in patients with Plasma brain natriuretic peptide levels(BNP)were compared before treatment and three months after the treatment. The number of admissions three months before treatment and three months after treatment was recorded,and the adverse reaction observed. Results Tiotropium pulmonary function was improved significantly, the number of daily use of beta agonists reduced, peripheral blood BNP decreased obviously, the number of acute exacerbation of seizures became less,no serious adverse reaction occurred. Conclusion Tiotropium bromide was effectiveness and safety in moderate to severe chronic obstructive pulmonary disease.
点击查看大图
下载:
